Author: Lauren Giorgio

Adelaide, Australia GPN Vaccines is pleased to announce that Dr Erin Brazel has been awarded a Junior Fellowship by the Passe & Williams Memorial Foundation. The prestigious fellowship secured by Dr Erin Brazel will support research on bacterial vaccines in a collaboration between GPN Vaccines and the...

Adelaide, Australia GPN Vaccines Ltd, a clinical-stage biotechnology company developing a Streptococcus pneumoniae vaccine to prevent life-threatening pneumonia, bacteraemia and meningitis, is pleased to announce positive safety and immunogenicity data from its Phase 1 trial of Gamma-PN, a non-adjuvanted whole cell-pneumococcal vaccine being investigated in adults aged...

GPN Vaccines was initially established with the goal of creating a vaccine capable of protecting children and adults against all serotypes of Streptococcus pneumoniae (the pneumococcus), a deadly pathogen responsible for killing up to two million people worldwide each year. Such a vaccine represents the...

Adelaide, Australia, 21st September 2022 - GPN Vaccines is pleased to announce publication of a landmark scientific paper in the prestigious journal mBio showing its novel pneumococcal vaccine, Gamma-PN, elicits a broad-spectrum, serotype-independent opsonophagocytic antibody response. This research, conducted in collaboration with the University of Adelaide,...

Adelaide, Australia, 1st April 2022 – GPN Vaccines is pleased to announce Dr Manon Cox has joined the Company’s Board of Directors. Dr Manon Cox is the Founder of NextWaveBio, providing scientific and strategic advice to biopharmaceutical companies around preclinical and clinical development, manufacturing and quality...

Protecting children and adults from the world’s foremost bacterial pathogen